Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | MTOR | P42345 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | TRIM33 | Q9UPN9 | 3/20 | 0.34 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30217954 | 0.79 | MAP3K14 (0.40) | MAP3K14PIK3CAMTORPIK3CGSCN10A | |
| SCHEMBL13676388 | 0.79 | CYP1A2 (0.53) | MAP3K14GAACYP1A2CYP2C9 | |
| SCHEMBL18785529 | 0.79 | MAP3K14 (0.50) | MAP3K14PIK3CAMTORTSHRMAPK10 | |
| SCHEMBL18041661 | 0.79 | PIK3CA (0.47) | MAP3K14PIK3CAMTORTSHRMAPK10 | |
| SCHEMBL3026036 | 0.79 | MAP3K14 (0.33) | MAP3K14PIK3CAMTORSCN10ACYP1A2 | |
| SCHEMBL381224 | 0.79 | MAP3K14 (0.46) | MAP3K14PIK3CAMTORTSHRMAPK10 | |
| SCHEMBL4821898 | 0.79 | MAP3K14 (0.54) | MAP3K14PIK3CAMTORTSHRMAPK10 | |
| SCHEMBL12998303 | 0.79 | PIK3CA (0.47) | MAP3K14PIK3CAMTORTSHRMAPK10 | |
| SCHEMBL22125606 | 0.79 | MAP3K14 (0.50) | MAP3K14PIK3CAMTORTSHRMAPK10 | |
| SCHEMBL3020269 | 0.79 | POLB (0.51) | MAP3K14FLT3AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114989167-B | 3,6-dibromo or 3-bromoimidazo [1,2-a ] pyridine derivative and synthesis method thereof | 江苏师范大学 | 2023-08-22 | — | — | CN | claimed |
| CN-114989167-A | 3,6-dibromo or 3-bromo imidazo [1,2-a ] pyridine derivative and synthesis method thereof | 江苏师范大学 | 2022-09-02 | — | — | CN | claimed |
| CN-114989167-B | 3,6-dibromo or 3-bromoimidazo [1,2-a ] pyridine derivative and synthesis method thereof | 江苏师范大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-114989167-A | 3,6-dibromo or 3-bromo imidazo [1,2-a ] pyridine derivative and synthesis method thereof | 江苏师范大学 | 2022-09-02 | — | — | CN | disclosed |
| CN-105037356-A | Synthesis method of 3,6-dibromoimidazole[1,2-a]pyridine | SHANDONG YOUBANG BIOCHEMICAL TECHNOLOGY CO LTD | 2015-11-11 | — | — | CN | disclosed |
| CN-105037356-A | Synthesis method of 3,6-dibromoimidazole[1,2-a]pyridine | SHANDONG YOUBANG BIOCHEMICAL TECHNOLOGY CO LTD | 2015-11-11 | — | — | CN | disclosed |
| US-8367662-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| EP-2212323-B1 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| EP-2212323-A2 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050183-A2 | IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210641-A1 | Organic Compounds | ALK, ACVR1, ACVRL1 | MAP3K14 1681/4885PIK3CA 741/4885MTOR 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.